ClinicalTrials.gg
WithdrawnNCT01420666Updated Jan 6, 2016

Maxi-Analgesic Osteoarthritis (OA) Study

A Phase 3 interventional study of Acetaminophen and Maxigesic 325 in Osteoarthritis, sponsored by AFT Pharmaceuticals, Ltd.. Withdrawn. Open to participants aged 45 Years to 80 Years. Per ClinicalTrials.gov, last updated 2016-01-06.

Sponsored by AFT Pharmaceuticals, Ltd. · Phase 3, Interventional, and Treatment

Why this study was withdrawn
The study was withdrawn for administrative reason

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
45 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 14 studies testing acetaminophen in Osteoarthritis — none open to participants now, none under way, none of them phase 3. Acetaminophen · Osteoarthritis.

Enrollment
12th of 14
0 · median 79
Phase 3
4 of 14
none open now
Registered
7th of 14
by date
Lead sponsor
1 of 14
AFT Pharmaceuticals, Ltd.

Among the 14 studies testing acetaminophen in Osteoarthritis, this one is the 12th largest by enrollment, is one of 4 in phase 3, and was the 7th registered.

Osteoarthritis

2,977 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

None of the 14 studies testing acetaminophen in Osteoarthritis is open now. The open studies under Osteoarthritis, anywhere →

About acetaminophen

Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.

This study: 45 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing acetaminophen in Osteoarthritis as a file.
02

Study summary

The purpose of this study is to determine whether the analgesic effects of Maxigesic USA are greater than acetaminophen, ibuprofen or placebo in patients who have painful osteoarthritis of the hip or knee.

Read the detailed description

Osteoarthritis is a significant and disabling disease in the developed world.

Published guidelines for medical management of osteoarthritis from expert groups, in general advocate acetaminophen as first line treatment. The European League Against Rheumatism (EULAR) guidelines (1)recommend acetaminophen should be first choice therapy in OA, and that NSAIDs should be reserved for those patients unresponsive to acetaminophen. The American College of Rheumatology Guidelines (2) recommend acetaminophen be considered as reasonable initial therapy in patients with mild to moderate OA pain and that NSAIDs be considered as an initial alternative in moderate to severe OA pain. The Canadian guidelines recommend acetaminophen for mild OA pain and NSAIDs for moderate to severe OA (3).

A Cochrane Review of acetaminophen in osteoarthritis concluded that NSAIDs were superior to acetaminophen for improving knee and hip pain in people with OA. However, it was noted that the size of the treatment effect was modest with NSAIDs appearing to be more effective in OA subjects with moderate-to-severe pain (4).

There are many situations in clinical practice where either acetaminophen alone or low dose ibuprofen is not sufficiently effective. In these cases the dose of acetaminophen cannot be increased to more than 4000mg/day due to toxicity concerns. In the case of ibuprofen the dose can be increased from 1200mg/day to 2400mg/day. However comparison of low dose ibuprofen with high dose showed gastrointestinal (GI) toxicity increased: the relative risk (RR) of GI complications increased from 1.6 (95% CI 0.8, 3.2) with low dose ibuprofen to 4.2 (95% CI 1.8, 9.8) with high dose ibuprofen (5). Ibuprofen is associated with a low risk of serious gastrointestinal complications, but this advantage is probably lost at doses above 1800 mg/day (6).

A simple combination treatment whereby both acetaminophen and ibuprofen can be taken together as one single tablet and at the same time each day would, if effective, have the advantage of increasing analgesia without having to raise the ibuprofen dose above 1200mg/day (1170mg if administered every 6 hours) and lose the improved safety profile associated with a lower dose of ibuprofen.

  1. Pendleton A, Arden N, Dougados M, Doherty M, Bannwarth B, Bijlsma JW, et al. EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2000;59(12):936-44.
  2. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum. 2000;43(9):1905-15.
  3. Tannenbaum H, Peloso PM, Russell AS, Marlow B. An evidence-based approach to prescribing NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis: The Second Canadian Consensus Conference. Can J Clin Pharmacol. 2000;7 Suppl A:4A-16A.
  4. Towheed TE, Maxwell L, Judd MG, Catton M, Hochberg MC, Wells G. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev. 2006(1):CD004257.
  5. Henry D, Lim LLY, Garcia Rodriguez LA, Perez Gutthann S, Carson JL, Griffin M, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: Results of a collaborative meta-analysis. British Medical Journal. 1996;312 (7046):1563-6.
  6. Henry D, McGettigan P. Epidemiology overview of gastrointestinal and renal toxicity of NSAIDs. Int J Clin Pract Suppl. 2003;Supplement.(135):43-9.
03

Conditions studied

  • Osteoarthritis

Browse trials for

04

Who can participate

Ages eligible
45 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provides written before initiation of any study-related procedures.
  • Have had symptoms of OA of the knee or hip for at least 6 months that has required analgesic medication.
  • Have confirmed radiological evidence of OA.
  • Be between 45 - 80 years of age inclusive, on the day of consent.
  • In the opinion of a physician, require long term medication for treatment of painful OA.
  • Have painful OA of the knee or hip with a pain score of at least 40 mm and no more than 80 mm on the WOMAC VAS pain scale at rest following a 3 - 7 day washout of existing analgesics.

Exclusion criteria

Exclusion Criteria:

  • Weigh less than 50 kg
  • Rheumatoid arthritis or other inflammatory arthritis.
  • Gout or recurrent episodes of pseudogout.
  • Paget's disease.
  • Articular fracture.
  • Ochronosis.
  • Acromegaly.
  • Haemochromatosis.
  • Wilson's Disease.
  • Primary Osteochondromatosis.
  • Heritable disorders (e.g. hypermobility).
  • Have received or taken oral or parenteral within 2 months or intra-articular hyaluronic acid within 9 months.
  • Has taken any single dose of an NSAID or acetaminophen within 12 hours prior to first dose of study drug
  • Known to be pregnant or possibly pregnant
  • Women of who, in the opinion of the investigator, are not using reliable .
  • Alcohol intake in excess of 14 units per week for females and 21 units per week for males.
  • Have a history of drug abuse.
  • Suffering from a neurological disorder relating to pain perception.
  • In the opinion of the investigator, unable to understand the visual analogue pain score.
  • Currently, or in the last 30 days, participating in a clinical trial involving another study drug.
  • Suffering from any other diseases or conditions which, in the opinion of the investigator, means that it would not be in the patients best interests to participant in this study.
  • to aspirin or other NSAID
  • Hypersensitivity to acetaminophen
  • Severe known haemopoietic, renal or hepatic disease,
  • History of gastric ulceration, indigestion, stomach pain or GI bleeding or bleeding disorders
  • Currently suffering from dehydration through diarrhoea and/or vomiting
  • History of severe asthma defined as previous steroid treatment or hospital admission within the last 5 years.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    Maxigesic 325

    Maxigesic 325 (acetaminophen 325 mg + ibuprofen 97.5mg), three tablets four times a day, orally, with food

    Drug: Maxigesic 325

  • Active comparator
    Acetaminophen

    Acetaminophen 325 mg, three tablets four times a day, orally, with food

    Drug: Acetaminophen

  • Active comparator
    Ibuprofen

    ibuprofen 97.5mg, three tablets four times a day, orally, with food

    Drug: Ibuprofen

  • Placebo comparator
    Placebo

    Placebo tablets

    Drug: Placebo

Interventions

  • Acetaminophen 325 mg, three tablets four times a day, orally, with food

    Also known as: Paracetamol

  • DrugMaxigesic 325

    Maxigesic 325 (Acetaminophen 325 mg+ ibuprofen 97.5mg), three tablets four times a day, orally, with food

    Also known as: Actaminophen/paracetamol + ibuprofen

  • Ibuprofen 97.5mg, three tablets four times a day, orally, with food

  • DrugPlacebo

    placebo, three tablets four times a day, orally, with food

06

What researchers measure

Primary outcomes

  1. WOMAC pain intensity VAS

    The difference between the week 13 average WOMAC pain intensity VAS and the baseline WOMAC VAS

    Time frame: 13 weeks

Secondary outcomes

  1. Time to peak analgesic effect

    Time to peak analgesic effect using the WOMAC VAS pain intensity score (the average pain intensity score of that week).

    Time frame: 13 weeks

  2. Time-adjusted SPID

    Time adjusted SPID obtained from the mean weekly WOMAC VAS pain intensity assessments over 13 weeks

    Time frame: 13 weeks

  3. Difference of WOMAC stiffness score

    Difference between the week 13 WOMAC stiffness score and the baseline WOMAC stiffness score

    Time frame: 13 weeks

  4. Difference of WOMAC function score

    Difference between the week 13 WOMAC function score and the baseline WOMAC function score

    Time frame: 13 weeks

  5. Time to rescue medication

    Tie to rescue medication (oxycodone)

    Time frame: 13 weeks

  6. Safety

    Adverse events (serious and non-serious) will be assessed during the blinded study period and up to 30 days after the last dose of study medication. Known NSAID adverse effects (i.e. GI ulceration, indigestion/stomach pain, bleeding, bronchospasm, water retention, renal failure, skin reactions and thromboembolic events) and known acetaminophen adverse effects (i.e. clinical evidence of hepatitis) will be compared between groups.

    Time frame: 13 weeks

  7. Time-adjusted WOMAC stiffness score

    Time-adjusted WOMAC stiffness score over 13 weeks

    Time frame: Over 13 weeks

  8. Time-adjusted WOMAC function score

    Time-adjusted WOMAC function score over 13 weeks

    Time frame: over 13 weeks

  9. Patient global assessment

    A categorical global pain rating will be obtained weekly during the double blind treatment period.

    Time frame: 13 weeks

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 6, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01420666
Lead sponsor
AFT Pharmaceuticals, Ltd.
Responsible party
Sponsor
First posted
Aug 22, 2011
Last update
Jan 6, 2016

Study contacts

John Moodie, Doctor
principal investigator · Clinical Trial New Zealand Ltd, 32 Kahikatea Drive, Hamilton, New Zealand

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Acetaminophen · Ibuprofen

Start the discussion